Stock DNA
Pharmaceuticals & Biotechnology
INR 10,485 Cr (Mid Cap)
92.00
40
0.00%
0.12
10.48%
6.91
Total Returns (Price + Dividend) 
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Intimation Regarding Change In Corporate Identification Number (CIN) And Listing Status Of The Company.
17-Nov-2026 | Source : BSEIntimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12-Nov-2026 | Source : BSEPursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended from time to time we would like to inform you that the officials of the Company will be attending an Investor
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
12-Nov-2026 | Source : BSETranscript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
38.5416
Held by 13 Schemes (12.18%)
Held by 23 FIIs (3.79%)
Satwani Holdings Llp (15.28%)
Rosewood Investments (14.07%)
7.81%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 4.35% vs -1.05% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 3.25% vs 399.62% in Jun 2026
Annual Results Snapshot (Standalone) - Mar'26
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period